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MDM2 and MDMX are the primary negative regulators of p53, which under normal con-
ditions maintain low intracellular levels of p53 by targeting it to the proteasome for rapid 
degradation and inhibiting its transcriptional activity. Both MDM2 and MDMX function 
as powerful oncogenes and are commonly over-expressed in some cancers, including 
sarcoma (~20%) and breast cancer (~15%). In contrast to tumors that are p53 mutant, 
whereby the current therapeutic strategy restores the normal active conformation of p53, 
MDM2 and MDMX represent logical therapeutic targets in cancer for increasing wild-
type (WT) p53 expression and activities. Recent preclinical studies suggest that there 
may also be situations that MDM2/X inhibitors could be used in p53 mutant tumors. 
Since the discovery of nutlin-3a, the first in a class of small molecule MDM2 inhibitors 
that binds to the hydrophobic cleft in the N-terminus of MDM2, preventing its association 
with p53, there is now an extensive list of related compounds. In addition, a new class 
of stapled peptides that can target both MDM2 and MDMX have also been developed. 
Importantly, preclinical modeling, which has demonstrated effective in vitro and in vivo 
killing of WT p53 cancer cells, has now been translated into early clinical trials allowing 
better assessment of their biological effects and toxicities in patients. In this overview, we 
will review the current MDM2- and MDMX-targeted therapies in development, focusing 
particularly on compounds that have entered into early phase clinical trials. We will 
highlight the challenges pertaining to predictive biomarkers for and toxicities associated 
with these compounds, as well as identify potential combinatorial strategies to enhance 
its anti-cancer efficacy.
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inTRODUCTiOn: RATiOnALe FOR TARGeTinG THe p53 
PATHwAY
The tumor suppressor protein p53, nominated “the guardian of the genome,” is mutated in ~50% 
of all human cancers. However, the incidence of p53 mutations differs significantly between cancer 
types, ranging from near universal mutation (~96%) in serous ovarian cancer to rare occurrence 
(<10%) in thyroid cancer (Figure  1A). This disparity provides therapeutic opportunities for 
targeting cancers with p53 wild-type (WT), in a distinct manner from those with p53 mutant can-
cers. Several preclinical studies have demonstrated that reconfiguration of mutant, to its normal, 
FiGURe 1 | Rationale for targeting p53 in cancers. (A) Frequency of alterations are shown with mutation (green), deletion (blue), amplification (red), and 
combination of alterations (gray) in p53, MDM2, and MDMX in cancers derived from cBioPortal (5) (http://www.cbioportal.org). Insert shows the mutual exclusivity 
observed between MDM2 expression and p53 deletion in sarcomas. (B) Schematic representation of inhibitors in clinical trials (yellow box) or in preclinical studies 
(blue box) targeting the p53–MDM2/X axis. Compounds are either small molecules (green circle) or peptide (blue circle).
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active WT p53 conformation, restores apoptosis and promotes 
tumor regression (1–3). Therapeutic targeting of mutant p53, 
using small molecule drugs, is in the most advanced state for 
PRIMA-1, and its derivative PRIMA-1MET, an approach which 
restores the normal, active conformation of p53, which has been 
previously explored in depth by Wiman and coworkers (4). In 
the current review, we focus on therapies that target MDM2 
and MDMX as a means of increase the stability of WT p53 and 
the consequences for patients with either WT p53 or mutant 
cancer cells.
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Regulation of p53 Stability by MDM2 and 
MDMX
The primary response to a variety of cellular insults and stresses is 
to concurrently activate and stabilize p53 within the cell. Activated 
p53 then drives a vast transcriptional program that arrests the cell 
cycle, promotes repair pathways, and in response to severe stress 
initiates apoptosis. Therefore, under normal conditions, it is criti-
cal that intracellular levels of p53 are kept low, which is achieved 
by the rapid degradation of p53 by the proteasome. This degra-
dation occurs in both ubiquitin-dependent (6) and ubiquitin-
independent mechanisms (7) and can be modulated by various 
signaling pathways including sumoylation, phosphorylation, 
acetylation, methylation, and glycosylation (8). Of these, ubiqui-
tination is the most important (6, 9) and the E3 ligase MDM2 is 
the primary negative regulator of p53 (10, 11), although several 
other E3 and E4 ligases of p53 also exist (8, 9). Mechanistically, 
engagement of the p53 N-terminal transactivation domain by the 
N-terminal of MDM2, facilitates its C-terminal RING finger E3 
ligase activity to transfer ubiquitin to multiple lysine residues of 
p53, located in central DNA-binding and C-terminal regulatory 
regions (8, 9). MDM2 ubiquitination of p53 (either mono- or 
poly-ubiquitination) negatively regulates its transcriptional activ-
ity. Mono-ubiquitin triggers nuclear export, while poly-ubiquitin 
targets nuclear p53 for degradation by the proteasome (12). 
Notably, the C-terminal of MDM2 is also able to bind with the 
C-terminal of the highly related protein MDMX (also known as 
HDMX and MDM4). Although MDMX does not possess E3 ligase 
activity, the MDM2–MDMX heterodimer ubiquitinates p53 with 
higher efficiency than MDM2 homodimers (13). MDMX, via its 
N-terminus, is able to bind p53 and efficiently inhibit its tran-
scriptional activity (14). Furthermore, MDM2 is transcriptionally 
up regulated by p53 and this negative-feedback loop associated 
with cyclical modulation of levels of both proteins, ensures that 
p53 levels remain low under normal conditions (15).
Targeting MDM2 and MDMX
Given the importance of both MDM2 and MDMX in regulating 
WT p53, it is unsurprising that they are commonly over-expressed 
in some cancers, including sarcoma (~20%) and breast (~15%) 
(Figure 1A). In this context, they function as powerful oncogenes 
and represent logical therapeutic targets for increasing WT p53 
expression and activities. The concept of MDM2 targeting was 
supported by the discovery of p14ARF (p19ARF in mice), an alternate 
reading frame protein produced from the CDKN2A locus (16, 
17). P14ARF binds to MDM2, sequestering it in the nucleolus and 
preventing it from targeting p53 for degradation (18, 19). More 
precisely, the capacity to bind and sequester MDM2 to the nucleus 
was assigned to a 22 amino acid fragment from the N-terminus 
of p14ARF, revealing a potential method for targeting MDM2 with 
small peptide inhibitors (20). The first successful realization of 
this potential came in 2004, when nutlin-3a was discovered by 
Vassilev et al. (21). Nutlin-3a potently binds to the hydrophobic 
cleft in the N-terminus of MDM2, preventing its association with 
p53. Importantly, it is highly effective killing of WT p53 cancer 
cells, both in vitro and in vivo in preclinical models, provided vali-
dation for its use. However, its poor bioavailability, high toxicity 
(discussed in greater detail below), and its limited effects on 
MDMX overexpressing cells (22–24) has prevented its translation 
to the clinic. Recent interest has switched to compounds that have 
better bioavailability and can target both MDM2 and MDMX. 
These new compounds can be broadly segregated according to 
their mode of action. The vast majority of preclinical and clinical 
small molecule inhibitors work similarly to nutlin-3a, binding to 
the N-terminal pocket of MDM2, inhibiting association with p53 
(Figure 1B). Despite the similarity in the N-terminal p53-binding 
domain of MDM2 and MDMX, most of these small molecule 
inhibitors bind with significantly less avidity to MDMX and are 
therefore primarily MDM2 specific (12). However, there are now 
several new peptide-based inhibitors that are capable of binding 
to the N-terminal of both MDM2 and MDMX (Table 1). In addi-
tion, several small molecule inhibitors, which bind specifically 
to the N-terminus of MDMX, have recently been developed and 
are currently undergoing preclinical testing (25, 26). In addition, 
there are now a growing number of new MDM2/X inhibitors that 
bind outside the N-terminus (Figure  1B). These include small 
molecules that inhibit the ubiquitin ligase activity of MDM2 
(27); disruptors of MDM2–MDMX heterodimerization (28); 
transcriptional inhibitors of both MDM2 (29, 30) and MDMX 
(31); MDM2 auto-ubiquitination activators (32, 33); inhibitors 
of HSP90 to disrupt MDMX protein folding; and molecules that 
directly engage p53 and prevent association with MDM2/X (34).
Cellular Responses to increased p53
Increased cellular p53 protein levels, resulting from MDM2/X 
inhibition, lead to a number of effects that can be simplified into 
the broad categories of cell cycle arrest and apoptosis. The decision 
between these two pathways is governed by the level and duration 
of p53 induction. Lower and cyclical levels of p53 induce arrest, 
while sustained levels of elevated p53 expression promotes death 
(35). Cell cycle arrest is primarily achieved through transcrip-
tional activation of p53 target genes, primarily p21 and GADD45, 
which block the activity of cyclin-dependent kinases (Cdk) 
and cause arrest in G1/S (36) and G2 phases, respectively (37). 
Interestingly, upregulation of p53 during mitosis does not delay 
mitotic progression, but it is an important requirement for arrest-
ing and eliminating aberrant polyploid cells in the subsequent 
G1 phase (38, 39). Continued p53 expression occurs when the 
damage or stress incurred cannot be repaired or resolved. These 
stresses continue to generate a signaling cascade (e.g., ATM/
ATR, Chk1/2) that leads to the continued stabilization of p53, 
and subsequently allows the accumulation of pro-apoptotic p53 
targets, including PUMA, Noxa, and Bim within the cell (40, 41). 
Once these proteins accumulate to sufficient levels, they trigger 
apoptosis (42, 43).
MDM2/X inHiBiTORS in CLiniCAL 
TRiALS
The majority of MDM2-targeted therapies currently in clinical 
development are small molecule inhibitors (Table 1). These have 
been crystallographically resolved and comprise derivatives 
that bind to MDM2 by mimicking Phe19, Trp23, and Leu26, 
TABLe 1 | MDM2 and MDMX inhibitors in clinical development.
MDM2 inhibitors in clinical development
Class and  
specificity
nature of 
compound
Compound Status p53 nCT identifier Company
Small molecule 
MDM2 antagonists
Cis-imidazoline RG7112 Phase I in advanced solid and hematological 
cancers, and liposarcoma (completed)
n/a NCT00559533
RG7112 with cytarabine Phase I in acute myelogenous leukemia 
(completed)
n/a NCT01635296
RG7112 with doxorubicin Phase I in soft tissue sarcoma (completed) n/a NCT01605526 Roche
RO5503781 Phase I in advanced solid cancers (completed) n/a NCT01462175
RO5503781 with 
cytarabine
Phase I in acute myelogenous leukemia (active 
but not recruiting)
n/a NCT01773408
RO5503781 with 
abiraierone
Phase I/II in advanced prostate cancer 
(recruiting)
n/a CRUKE/12/032
Spiro-oxindole SAR405838 Phase I in advanced solid cancers (active but 
not recruiting) 
n/a NCT01636479 Sanofi-Aventis
SAR405838 with 
pimasertib
Phase I in advanced solid cancers (recruiting) n/a NCT01985191
Imidazothiazole DS-3032b Phase I in advanced solid cancers (recruiting) n/a NCT01877382 Daiichi Sankyo
Dihydroisoquinolinone CGM-097 Phase I in advanced solid tumors (recruiting) wtp53 NCT01760525
n/a HDM201 Phase I in advanced solid and hematological 
cancers (recruiting)
wtp53 NCT02143635 Novartis
HDM201 with ribociclib Phase Ib/II in liposarcoma (recruiting) wtp53 NCT02343172
Piperidines MK4828 with cytarabine Phase I in acute myelogenous leukemia 
(terminated)
n/a NCT01451437 Merck
Piperidinone AMG232 Phase I in advanced solid cancers and multiple 
myeloma (recruiting)
n/a NCT01723020 Amgen
AMG 232 with trametinib 
and dabrafenib
Phase Ib/IIa in metastatic melanoma 
(recruiting)
n/a NCT02110355
Pyrrolidine RG7388 Phase 1 in polycythemia vera and essential 
ihrombocythemia (recruiting)
n/a NCT02407080 Pegasys
Stapled peptide 
MDM2/X inhibitor
Peptide ALRN-6924 Phase I in advanced solid cancers (recruiting) wtp53 NCT02264613 Aileron
Data extracted from http://www.clinicaltrials.gov, accessed 1st December 2015.
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which are key residues engaged by p53. ALRN-6924 (Aileron 
Therapeutics) belongs to a different class of therapeutics, which 
are stapled peptides designed to disrupt p53 interaction with 
both MDM2 and MDMX. A number of these compounds are 
also being evaluated clinically in combination with cytotoxics 
(doxorubicin and cytarabine), and also molecular-targeted thera-
pies, including ribociclib (CDK4/6 inhibitor), dabrafenib (BRAF 
inhibitor), trametinib, and pimasertinib (MEK1/2 inhibitors). 
A number of these trials have excluded patients with p53 mutant 
tumors; however, the majority have not defined a clear biomarker 
for selection criteria, in keeping with the primary end points of 
safety and tolerability. It is of interest that a number of these phase 
1 trials have yet to be reported even though accrual was started 
over 3 years ago, which is unusually long in a phase 1 setting.
RG7112 is the most developed in this class of compounds, 
and preclinical studies demonstrate strong binding to MDM2, 
and effective apoptosis, particularly in MDM2-amplified tumors 
(44). One of first clinical trials reported was in patients with lipo-
sarcoma, a tumor characterized by a high proportion of MDM2 
gene amplification and wild-type p53 (45). The primary end point 
in this small neoadjuvant study of 20 patients was to assess tumor 
biomarkers of p53 pathway activation and cell proliferation. The 
results demonstrated an increase in intratumoral p53, p21, and 
macrophage-inhibitory cytokine 1 (MIC1, a secreted protein 
product of p53) concentrations, an increase in MDM2 mRNA 
expression and a small decrease in Ki-67 positive cells in the 
treated compared to the pretreated samples. Clinically, the results 
were modest, with one partial response and stable disease in 70% 
of the cohort. Importantly, there were serious adverse events 
(grade 3 or 4) experienced by 40% of the patients, the majority of 
which were hematological in nature.
RG7112 has also been evaluated in a phase 1 trial of patients 
with relapsed/refractory leukemia, such as AML, ALL, CML, and 
CLL (46). The most common toxicities were gastrointestinal and 
hematological in nature, 22% of patients experiencing grade 3 
and 4 febrile neutropenia. There was clinical activity, particularly 
in the AML cohort, whereby 5 out of 30 evaluable patients 
achieved either a complete or partial response, and another 9 
patients had stable disease. These numbers suggest useful single 
agent clinical activity, given the refractory nature of their disease 
to other therapies. MDM2 inhibition resulted in p53 stabilization 
and transcriptional activation of p53 target genes. Interestingly, 
two patients who had p53 mutations (G266E and R181L) also 
responded to RG7112 in this trial. The G266E is a gain-of-
function (GOF) p53 mutation that upregulates CXC-chemokine 
expression and enhances cell migration (47), while R181L is 
capable of inducing MDM2 and instigating a cell cycle arrest, 
but not apoptosis (48). Consequently, these mutants (G266E and 
R181L) may still be sensitive to MDM2/X inhibitors, and hence 
patients with these mutations may benefit from these inhibitors.
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Assessing the effects that MDM2/X inhibitors in the context of 
the various GOF p53 mutants will be of significant importance, 
as MDM2/X inhibition has the potential to increase the levels 
of GOF p53 mutants. Several GOF mutants have been shown 
to increase cell proliferation, metabolism, invasion, and chem-
oresistance in cancer cells (49–53). Consequently, inhibition of 
MDM2/X could place selective pressure on cancer cells with GOF 
p53 mutations, driving the clonal evolution of more aggressive 
cancer cells and exacerbating tumor growth and metastasis in 
patients. Alternatively, a recent preclinical study demonstrated 
that the novel small molecule NSC59984 activates p73, resulting 
in an MDM2-dependent degradation of GOF p53 and subse-
quent inhibition of tumor growth (54). Other possible explana-
tions for the varied patient response include multiple clones 
being present with the tumor (only some of which are mutant), a 
retention of one wild-type allele, certain p53 mutations may still 
have functional p53 activity (55). Taken together, it is clear that 
much more work needs to be done to clearly identify biomark-
ers to improve patient selection for clinical trials of MDM2/X 
inhibitors. Furthermore, understanding the heterogeneity of p53 
expression and the specific mutations within a patient’s tumor 
prior, during and post treatment will also be of considerable 
importance for determining the suitability of treatment with 
MDM2/X inhibitors.
The clinical effect of MDM2 inhibitors on p53 reactivation, 
range from cytostasis to apoptosis, and a combination strategy 
may be more efficacious in certain contexts. Preclincal mod-
eling with nutlin-3a has demonstrated improved anti-cancer 
activity in combination with cytotoxic- and molecular-targeted 
therapies, in different tumor types (45); however, the toxicity 
profile of the combination partner is a critical determinant of 
the success of such an approach clinically. The high incidence 
of hematological toxicities in the clinical trials of RG7112 
would suggest that therapies with an overlapping side effect 
profile would not be suitable as combination partners (45, 46). 
A number of clinical trials combining MDM2 inhibitors with 
cytotoxics have completed accrual but have yet to be reported 
(Table 1).
TOXiCiTieS
A concern of p53 reactivating therapies is its effect on normal 
cells. These include the stabilization of p53 resulting in increased 
apoptosis in these cells. This was reflected in the clinical trial 
of RG7112 in lipoma, whereby the most common toxicity 
was hematological in nature, with a reported 30% of patients 
experiencing grade 4 neutropenia, and 15% experiencing some-
times prolonged grade 4 thrombocytopenia (45, 46). Whether 
hematologic toxicity correlates with prior exposure to genotoxic 
therapies is not known. There are also reports of an increased 
incidence of p53 mutations following prolonged nutlin-3a 
exposure (56), and concerns about this effect on the develop-
ment of new cancers (57). Other potential off-target effects on 
MDM2 inhibitors include the loss of its ability to ubiquitinate 
other proteins, such as the steroid hormone receptors [estrogen 
receptor (ER) and androgen receptor (AR)] and Rb, as well as 
interference with MDM2’s role in DNA repair and modifying 
chromatin structure (58). The clinical relevance of these poten-
tial long-term toxicities have not been reported in the current 
early phase trials.
COnCLUSiOn/PeRSPeCTive
Protein–protein interactions, once considered to be a major 
hurdle to p53 therapeutic development, can now be targeted 
with a growing number of small molecule inhibitors and stapled 
peptides. The strategies to overcome this Achilles heel in many 
cancers are increasingly varied, and build upon an understanding 
of the crystallographic structure of p53 and its interactions with 
its major inhibitors. Most of the major pharmaceutical companies 
have one or more lead compounds targeting MDM2/X, and many 
of these have only recently progressed from preclinical develop-
ment into early phase clinical trials.
The effect of MDM2/X-targeting therapies range from 
cytostasis to apoptosis, and combinatory approaches with other 
cytotoxic therapies or therapies that target other major onco-
genic pathways are logical approaches, and may allow for lower 
and better tolerated doses of both drugs to be administered. For 
example, in p53 mutant tumors, protection of normal cells can 
be achieved by triggering p53-dependent cytostatic effects with 
short, pulsed exposure to MDM2 inhibitors. This cyclotherapy 
can reduce the toxic side effect of chemotherapy in these p53 
mutant patients (59). Alternatively, recent preclinical evidence 
has demonstrated that inhibition of MDM2 with nutlin-3a pre-
vents repair of DNA damage, providing synthetic lethality with 
genotoxic agents, such as cisplatin (60). Importantly, this effect 
was independent of p53 status and could provide a rational for 
examining MDM2 combination therapy in p53 mutant patients. 
Getting the therapeutic index right is critical in patients. It is 
not surprising that hematological toxicities have been the most 
commonly reported and dose-limiting toxicities in the trials 
reported so far (45, 46). Long-term follow-up is also critical to 
evaluate for the clinical relevance of the potential effects of an 
increase in p53 mutations and other off-target effects of this class 
of compounds.
The three major biomarkers that have been used to evaluate 
therapeutic responses to MDM2/X inhibitors are p53 status, 
MDM2, and MDMX levels. Interestingly, the over expression of 
MDM2, MDMX, or mutation of p53 are often mutually exclusive. 
For example, liposarcoma, which is one of the first tumors in 
which MDM2 inhibitors have been evaluated (45), shows highly 
significant tendency toward mutual exclusivity (p-value <0.001) 
between overexpression of MDM2 (19%) and p53 mutation 
(12%) (Figure 1A) (5). Other tumors with similar trends of exclu-
sivity include glioblastoma multiforme, melanoma, bladder, lung 
andenocarcioma, prostate, and ER-positive breast cancers. These 
tumors present an obvious starting point for trialing MDM2/X 
inhibitors in patients. The high rate of MDM2 overexpression 
in prostate and ER-positive breast cancers, and the ability of 
MDM2 inhibitors to ubiquitinate steroid hormone receptors, has 
led to the evaluation of this class of drugs in combination with 
endocrine therapies (CRUKE/12/032). It has also been shown 
that estradiol modulates a subset of p53 and ER target genes that 
can predict the relapse-free survival of patients with ER-positive 
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breast cancer, and that p53 activation with nutlin in combination 
with fulvestrant, a selective ER degrader, led to a greater degree 
of apoptosis in vitro (61).
Given the risk of mutations in p53 driving resistance 
to MDM2/X inhibitors, additional biomarkers need to be 
identified to maximize the chances of clinical success. This is 
highlighted by evidence that p53 mutation status as currently 
measured clinically, may not be an accurate representation of 
functional p53 activity (46). In support, the recent discovery 
that MDM2 inhibitor sensitivity could be predicted by a panel 
of 13 p53 transcriptional target genes (62) was subsequently 
shown to be based on a significant number of miss-classified 
p53 mutant cell lines (63). Removal of these lines unfortunately 
abolished the predicative power of the gene signature. An 
alternative approach would be to select for tumors with MDM2 
amplification given the mutual exclusivity of p53 mutations and 
MDM2 amplification (64). However, MDM2 and MDMX have 
different and cooperative inhibitory effects on p53 activity, and 
therefore inhibitors of one may not be as effective in the setting 
of raised levels of the other protein (23). Thus, these biomark-
ers, while logical in their choice, unless further improved upon, 
may potentially exclude patients who may benefit from these 
therapies.
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